Apex BiotechnologyTPE:1733 -0.17%81 EBITDA Margin % is 16.83% as of Dec. 2025, which is 28% above its 10-year median of 13.10. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 935 Biotechnology companies, Apex Biotechnology ranks better than 77.22% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Apex Biotechnology's EBITDA for the
three
months ended in Dec. 2025 was NT$74 Mil. Apex Biotechnology's Revenue for the
three
months ended in Dec. 2025 was NT$439 Mil. Therefore, Apex Biotechnology's EBITDA margin for the quarter that ended in Dec. 2025 was 16.83%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Apex Biotechnology EBITDA Margin % Related Terms
Apex Biotechnology EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Apex Biotechnology's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a EBITDA Margin % of 16.83% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apex Biotechnology and its competitors. This is 28% above median its historical median of 13.10. Over the past decade, Apex Biotechnology's EBITDA Margin % has ranged from 9.27 to 13.75. According to the industry distribution chart, Apex Biotechnology ranks #213 out of 935 companies in the Biotechnology industry, placing it in the top 22.8%.
Is Apex Biotechnology's EBITDA Margin % too high?
Apex Biotechnology's current EBITDA Margin % of 16.83% is 28% above median its 10-year median of 13.10. Over the past 10 years, this metric has ranged from a low of 9.27 to a high of 13.75. Based on the distribution chart, Apex Biotechnology ranks #213 out of 935 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #213 out of 935 companies for EBITDA Margin %. This places Apex Biotechnology in the top 23% of its industry — outperforming the majority of peers. Historically, Apex Biotechnology's own EBITDA Margin % has ranged from 9.27 to 13.75 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current EBITDA Margin % is 16.83%, which is 28% above median its own 10-year median of 13.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current EBITDA Margin % is 16.83%, which is 28% above median its 10-year median of 13.10. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current EBITDA Margin % is 16.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
EBITDA Margin %: 16.83% (28% above median its 10-year median of 13.10)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
